한빛사논문
- 조회1,344
Nem Singha,1, Jungryun Kima,1, Jaewon Kima,1, Kyungwoo Leea,1, Zehra Zunbula, Injun Leea, Eunji Kima, Sung-Gil Chib, Jong Seung Kima
aDepartment of Chemistry, Korea University, Seoul, 02841, South Korea
bDepartment of Life Science, Korea University, Seoul, 02841, South Korea
1Equally contributed.
Corresponding authors: Sung-Gil Chi, Jong Seung Kim
Abstract
Nanomedicines for drug delivery and imaging-guided cancer therapy is a rapidly growing research area. The unique properties of nanomedicines have a massive potential in solving longstanding challenges of existing cancer drugs, such as poor localization at the tumor site, high drug doses and toxicity, recurrence, and poor immune response. However, inadequate biocompatibility restricts their potential in clinical translation. Therefore, advanced nanomaterials with high biocompatibility and enhanced therapeutic efficiency are highly desired to fast-track the clinical translation of nanomedicines. Intrinsic properties of nanoscale covalent organic frameworks (nCOFs), such as suitable size, modular pore geometry and porosity, and straightforward post-synthetic modification via simple organic transformations, make them incredibly attractive for future nanomedicines. The ability of COFs to disintegrate in a slightly acidic tumor microenvironment also gives them a competitive advantage in targeted delivery. This review summarizes recently published applications of COFs in drug delivery, photo-immuno therapy, sonodynamic therapy, photothermal therapy, chemotherapy, pyroptosis, and combination therapy. Herein we mainly focused on modifications of COFs to enhance their biocompatibility, efficacy and potential clinical translation. This review will provide the fundamental knowledge in designing biocompatible nCOFs-based nanomedicines and will help in the rapid development of cancer drug carriers and theranostics.
논문정보
- Review Paper
- 2022년 09월 (BRIC 등록일 2022-12-15)
- 국내 연구진
- 생명과학 > 노화/암생물학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
